Cytokinetics, Incorporated (CYTK)

Cytokinetics' stock experienced volatility in the past six months. In early May 2025, the stock price saw sharp drops after the FDA extended the review period for aficamten due to the omission of a REMS. The stock price fell by 12.9% on May 2, 2025, and further declined on May 7, 2025. Despite these setbacks and associated lawsuits, the stock has rebounded, with a 1-month share price return of 18.6% and a 90-day gain of 57% as of October 19, 2025. As of October 24, 2025, the closing stock price was $57.83.

Specific demand seasonality for Cytokinetics' individual products is not detailed, but cardiovascular diseases, which they target, can exhibit seasonal patterns with winter peaks and clusters after cold snaps and peaks linked to heat waves. Neuromuscular disease therapeutics represent a significant and growing market, with expectations of over 10% annual expansion, driven by innovative treatments and research; however, no specific seasonality for the demand of Cytokinetics' neuromuscular products has been identified.

Cytokinetics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel small molecule therapeutics. It operates in the biotechnology and pharmaceutical industries, with a focus on drug discovery and development in the cardiovascular biopharmaceutical sector. The company develops muscle activators and inhibitors for diseases characterized by impaired muscle function, including cardiovascular and neuromuscular conditions. Key investigational medicines include aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil for heart failure, reldesemtiv for amyotrophic lateral sclerosis, CK-586 for heart failure, and CK-089 for muscular dystrophy.

Cytokinetics, Inc. is headquartered in South San Francisco, California. The company is preparing for the commercial launch of aficamten in the U.S., Europe, and China and has a collaboration for commercialization in Japan.

Cytokinetics' brand reputation has been impacted by class-action lawsuits alleging that the company misled investors regarding the regulatory timeline for aficamten and failed to disclose the omission of a required safety strategy (REMS) from the initial NDA submission. These legal actions have shaken investor sentiment due to the regulatory setback.

Cytokinetics, Inc. has a significant institutional ownership presence. As of October 14, 2025, 767 institutional owners and shareholders held a total of 164,544,297 shares. Major institutional shareholders include T. Rowe Price Investment Management, Inc., BlackRock, Inc., Vanguard Group Inc, Fmr Llc, Wellington Management Group Llp, State Street Corp, VGHCX - Vanguard Health Care Fund Investor Shares, IJH - iShares Core S&P Mid-Cap ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Deep Track Capital, LP. Approximately 40.05% to 63.04% of the company's stock is owned by institutional investors, while insiders own about 0.74%.